These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. A practical approach to the diagnosis of polycystic ovary syndrome. Chang RJ Am J Obstet Gynecol; 2004 Sep; 191(3):713-7. PubMed ID: 15467530 [TBL] [Abstract][Full Text] [Related]
3. Prevalence of nonclassic adrenal hyperplasia (NCAH) in hyperandrogenic women. Fanta M; Cibula D; Vrbíková J Gynecol Endocrinol; 2008 Mar; 24(3):154-7. PubMed ID: 18335331 [TBL] [Abstract][Full Text] [Related]
4. Comparison of clinical and laboratory characteristics of cases with polycystic ovarian syndrome based on Rotterdam's criteria and women whose only clinical signs are oligo/anovulation or hirsutism. Hassa H; Tanir HM; Yildiz Z Arch Gynecol Obstet; 2006 Jul; 274(4):227-32. PubMed ID: 16691383 [TBL] [Abstract][Full Text] [Related]
5. Extensive clinical experience: relative prevalence of different androgen excess disorders in 950 women referred because of clinical hyperandrogenism. Carmina E; Rosato F; Jannì A; Rizzo M; Longo RA J Clin Endocrinol Metab; 2006 Jan; 91(1):2-6. PubMed ID: 16263820 [TBL] [Abstract][Full Text] [Related]
6. Polycystic ovary syndrome: a review for dermatologists: Part I. Diagnosis and manifestations. Housman E; Reynolds RV J Am Acad Dermatol; 2014 Nov; 71(5):847.e1-847.e10; quiz 857-8. PubMed ID: 25437977 [TBL] [Abstract][Full Text] [Related]
7. Obesity, weight loss, and the polycystic ovary syndrome: effect of treatment with diet and orlistat for 24 weeks on insulin resistance and androgen levels. Panidis D; Farmakiotis D; Rousso D; Kourtis A; Katsikis I; Krassas G Fertil Steril; 2008 Apr; 89(4):899-906. PubMed ID: 17980364 [TBL] [Abstract][Full Text] [Related]
11. Current approaches to the diagnosis and treatment of polycystic ovarian syndrome in youth. Harwood K; Vuguin P; DiMartino-Nardi J Horm Res; 2007; 68(5):209-17. PubMed ID: 17426408 [TBL] [Abstract][Full Text] [Related]
12. What every physician should know about polycystic ovary syndrome. Rosenfield RL Dermatol Ther; 2008; 21(5):354-61. PubMed ID: 18844713 [TBL] [Abstract][Full Text] [Related]
13. Modified dexamethasone and gonadotropin-releasing hormone agonist (Dx-GnRHa) test in the evaluation of androgen source(s) in hirsute women. Bidzińska B; Tworowska U; Demissie M; Milewicz A Przegl Lek; 2000; 57(7-8):393-6. PubMed ID: 11109312 [TBL] [Abstract][Full Text] [Related]
14. Prolactin is associated with metabolic risk and cortisol in 1007 women with polycystic ovary syndrome. Glintborg D; Altinok M; Mumm H; Buch K; Ravn P; Andersen M Hum Reprod; 2014 Aug; 29(8):1773-9. PubMed ID: 24903198 [TBL] [Abstract][Full Text] [Related]
16. Treatment options of polycystic ovary syndrome in adolescence. Zapanti E; Kiapekou E; Loutradis D Pediatr Endocrinol Rev; 2006 Jan; 3 Suppl 1():208-13. PubMed ID: 16641862 [TBL] [Abstract][Full Text] [Related]
17. Ovulation after glucocorticoid suppression of adrenal androgens in the polycystic ovary syndrome is not predicted by the basal dehydroepiandrosterone sulfate level. Azziz R; Black VY; Knochenhauer ES; Hines GA; Boots LR J Clin Endocrinol Metab; 1999 Mar; 84(3):946-50. PubMed ID: 10084576 [TBL] [Abstract][Full Text] [Related]
18. Detection of functional ovarian hyperandrogenism in women with androgen excess. Ehrmann DA; Rosenfield RL; Barnes RB; Brigell DF; Sheikh Z N Engl J Med; 1992 Jul; 327(3):157-62. PubMed ID: 1319000 [TBL] [Abstract][Full Text] [Related]